Citi Downgrades Baxter International Inc(BAX.US) to Sell Rating, Cuts Target Price to $17
Citigroup Downgrades Baxter International to Sell From Neutral, Adjusts PT to $17 From $19
Notable Healthcare Headlines for the Week: UnitedHealth, Boston Scientific, and Eli Lilly in Focus
Top Stock Gainers Today, 5/19/26
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Astrana Health (ASTH) and Baxter International (BAX)
TD Cowen Maintains Baxter International Inc(BAX.US) With Hold Rating, Maintains Target Price $20
BofA Securities Maintains Baxter International Inc(BAX.US) With Hold Rating, Maintains Target Price $24
Analysts Conflicted on These Healthcare Names: Cardinal Health (CAH), Baxter International (BAX) and Cigna (CI)
Analysts Offer Insights on Healthcare Companies: Baxter International (BAX) and Capricor Therapeutics (CAPR)
Baxter Updates Executive Severance Plan and Governance Framework
Artificial Organs and Bionics Market to Hit US$ 50.7 Billion by 2030, Driven by Next-Gen Implants | Wissen Research
Barclays Maintains Baxter International Inc(BAX.US) With Buy Rating, Maintains Target Price $27
Research Alert: CFRA Keeps Hold Rating On Shares Of Baxter International Inc.
Baxter International (BAX) Receives a Hold From Stifel Nicolaus
Analysts Are Bullish on Top Healthcare Stocks: Alkermes (ALKS), Baxter International (BAX)
Healthcare Earnings Impress With 86% Beat Rate, yet Sector Lags: Earnings Scorecard
Stifel Nicolaus Adjusts Baxter International Price Target to $19 From $20
Barclays Adjusts Baxter International Price Target to $27 From $25
Baxter Profit Plunges 35% As Tariffs, Costs Bite
Goldman Sachs Maintains Baxter International Inc(BAX.US) With Hold Rating, Cuts Target Price to $19